EPS for Achaogen, Inc. (AKAO) Expected At $-0.92

April 23, 2018 - By Peter Erickson

Achaogen, Inc. (NASDAQ:AKAO) LogoInvestors sentiment increased to 1.32 in 2017 Q4. Its up 0.16, from 1.16 in 2017Q3. It improved, as 16 investors sold Achaogen, Inc. shares while 21 reduced holdings. 22 funds opened positions while 27 raised stakes. 29.75 million shares or 6.36% less from 31.77 million shares in 2017Q3 were reported.
Tiaa Cref Mngmt Limited Co has 0% invested in Achaogen, Inc. (NASDAQ:AKAO). Deutsche Commercial Bank Ag stated it has 0% of its portfolio in Achaogen, Inc. (NASDAQ:AKAO). Proshare Advisors Limited Liability invested 0% in Achaogen, Inc. (NASDAQ:AKAO). First Midwest Savings Bank Division has 374,007 shares for 0.5% of their portfolio. Parallax Volatility Advisers Limited Partnership owns 5,308 shares. Stanley reported 69,889 shares stake. Barclays Plc invested 0% in Achaogen, Inc. (NASDAQ:AKAO). Financial Architects Inc owns 2,603 shares. Susquehanna Interest Group Incorporated Llp holds 0% in Achaogen, Inc. (NASDAQ:AKAO) or 128,313 shares. Northern owns 376,021 shares. Sei Invs Company accumulated 88,000 shares. Iguana Mngmt Ltd Liability stated it has 75,000 shares or 0.52% of all its holdings. Great West Life Assurance Can accumulated 2,200 shares. The Connecticut-based Point72 Asset Management Lp has invested 0.07% in Achaogen, Inc. (NASDAQ:AKAO). New York-based Retail Bank Of Mellon Corp has invested 0% in Achaogen, Inc. (NASDAQ:AKAO).

Since December 18, 2017, it had 9 buys, and 5 insider sales for $10.50 million activity. The insider Hillan Kenneth J. sold 4,606 shares worth $49,146. $17,499 worth of Achaogen, Inc. (NASDAQ:AKAO) was sold by Wise Blake. The insider Schilke Tobin sold 1,108 shares worth $11,822. Another trade for 1,282 shares valued at $13,679 was made by Swem Lee on Wednesday, February 21.

Analysts expect Achaogen, Inc. (NASDAQ:AKAO) to report $-0.92 EPS on May, 14.They anticipate $0.41 EPS change or 80.39 % from last quarter’s $-0.51 EPS. After having $-0.98 EPS previously, Achaogen, Inc.’s analysts see -6.12 % EPS growth. The stock increased 2.88% or $0.375 during the last trading session, reaching $13.385. About 1.18M shares traded or 0.00% up from the average. Achaogen, Inc. (NASDAQ:AKAO) has declined 41.74% since April 23, 2017 and is downtrending. It has underperformed by 53.29% the S&P500.

Achaogen, Inc. (NASDAQ:AKAO) Ratings Coverage

Among 6 analysts covering Achaogen (NASDAQ:AKAO), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Achaogen had 7 analyst reports since October 24, 2017 according to SRatingsIntel. Stifel Nicolaus maintained the shares of AKAO in report on Wednesday, February 28 with “Buy” rating. The firm has “Buy” rating by Needham given on Wednesday, February 28. The stock of Achaogen, Inc. (NASDAQ:AKAO) earned “Buy” rating by Mizuho on Wednesday, February 28. The firm has “Buy” rating given on Tuesday, January 2 by Cowen & Co. On Wednesday, February 14 the stock rating was maintained by Wedbush with “Buy”. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, November 9.

Achaogen, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant gram-negative infections in the United States. The company has market cap of $598.65 million. The firm is principally developing plazomicin, which is in Phase III clinical trial for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR Enterobacteriaceae comprising carbapenem-resistant Enterobacteriaceae. It currently has negative earnings. It is also involved in the research and development of antipseudomonal LpxC inhibitor compounds for the treatment of bacterial infections; and therapeutic antibody discovery program.

Achaogen, Inc. (NASDAQ:AKAO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.